Healthcare ❯Pharmaceuticals ❯Vaccine Development

COVID-19 Vaccines

Approval Process Biontech and Pfizer Moderna Spikevax

Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop Over 20%

The biotech firm cites declining COVID-19 vaccine demand, slow RSV vaccine adoption, and increased competition as key challenges.

BioNTech and Pfizer Agree to $1.2 Billion Settlement Over U.S. Vaccine Patent Disputes